Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

CEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial is planned to enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.

Third Quarter and First Nine Months 2012 Financial Results (Unaudited)
InterMune reported total revenue in the third quarter of 2012 of $7.5 million, compared with $0.1 million in the third quarter of 2011.  Third quarter 2012 revenue included $0.5 million of favorable adjustments to revenue primarily related to favorable foreign exchange fluctuations.  InterMune reported total revenue for the first nine months of 2012 of $18.0 million, compared with $2.7 million in the first nine months of 2011.  Revenue was almost entirely from sales of Esbriet in Germany, as active promotion in the largest of the mid-sized countries for which pricing and reimbursement is approved began in September of 2012.  Included in the third quarter 2012 results was the effect of the approximate 11 percent German price decrease of Esbriet, which became effective on September 15, 2012 as previously announced.  Total revenue in the first nine months of 2011 included $2.6 million of revenue from the company's research collaboration with Roche, which was completed in June 2011.Research and development (R&D) expenses in the third quarter of 2012 were $26.2 million, compared with $17.0 million in the third quarter of 2011, an increase of 54 percent.  R&D expenses were $74.6 million for the nine months ended September 30, 2012, compared with $54.0 million in the same period of 2011, an increase of 38 percent.  Higher R&D expenses in both the three- and nine-month periods of 2012, compared with the same periods in 2011, reflect expenses related to conduc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... 2014 Research and Markets ... N-acetylcysteine Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study ... industry. The report provides a basic ... and industry chain structure. The N-acetylcysteine market analysis ...
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global N-acetylcysteine Industry Report 2014 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Tips for Better Blood ... Sugar Management, BRIDGEWATER, N.J., ... with diabetes, Emmy nominated actress and,Broadway star Aida Turturro is teaming up ... diabetes to reach,better levels of blood sugar control. Ms. Turturro,s personal story ...
... security guards, police officers and armed forces into Robocops, repelling ... in carbon nanotechnology however could give those in the line ... of damage. , A research paper published in ... Centre for Advanced Materials Technology at the University of Sydney ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: ... 7ACA production has been successfully implemented on ... validates the Company,s research,and development efforts to ... immediate benefits to production operations by,increasing production ...
Cached Biology Technology:Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 2Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 3Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 4Using nanotech to make Robocops 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... engineering professor and his doctoral student have designed a ... water collected from fog and dew., The device could ... deserts around the globe., Cheng Luo, professor in the ... candidate in the same College of Engineering department, published ... of ACS, (American Chemical Society) Applied Materials ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2Shorebird's beak inspires UT Arlington research on water collection 2
... The majority of rare diseases are hereditary. But despite ... exact cause remains unclear. The discovery of the underlying ... diagnosis and the development of innovative approaches to their ... Genetics and the Institute of Medical Genetics at the ...
... The incidence of psychotic disorders varies greatly ... course, and treatment response across individuals. High rates ... cannabis users, and traumatised individuals reflect the causal ... progress in the area of molecular genetics, has ...
... the environment specifically to creatures that live in water ... Carolina State University toxicologists. In a study published in ... NC State researchers show that water fleas take up nitrates ... fertilizers and convert those chemicals into nitric oxide. Nitric ...
Cached Biology News:All genes in 1 go 2Developmental gene-environment interactions: A model for psychosis 2Developmental gene-environment interactions: A model for psychosis 3Developmental gene-environment interactions: A model for psychosis 4Developmental gene-environment interactions: A model for psychosis 5Developmental gene-environment interactions: A model for psychosis 6Fertilizer chemicals linked to animal developmental woes 2
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Biology Products: